Bone Strength Take Care.

The gap this formula speaks to.

Public health figures the engine matched to this formula's ingredients. Reported by their source, cited and dated, never written by the brand.

Population figures from public health data. Context for the category, not a statement about any individual and not a claim about this product.

Every one of these is a fact the engine could ground.

Each line below was derived from this formula's own record at the time of verification. Nothing here was written by the brand, and nothing can be added that the evidence does not carry.

• Studied in people21 human studies on Magnesium back this formula, each one cited.
• A mechanism that is settledHow Vitamin D3 and Vitamin K1 work is settled pharmacology.
• Studied together, not just separatelyVitamin D3 and Vitamin K1 have been studied together, not only separately.
• Recent work on the recordThe most recent study on this record was published in 2026.
• Serving amount inside the studied rangeEach serving carries 45 mcg of Vitamin K2, inside the range the published research used.
• A stated daily maintenance amountVitamin K2 is here at a daily maintenance amount, which is what a daily supplement is for.
• Why this formatIt is a tablet, so the amount per serving is fixed and it stores well.
• The exact form, describedThe label names its forms exactly: Vitamin D3 in a carrier oil, lanolin-derived, Vitamin K1 in an oil-filled softgel, MK-7, all-trans menaquinone-7. The record says what each one is and what it suits.
• Full label disclosureEvery ingredient on this label carries its own declared amount.
• Where it comes from and how it is madeVitamin D3 is made by more than one route.
• Positions this formula already qualifies forThis formula already qualifies for positions beyond the one it is sold into, on the evidence it carries.
• A position nobody is holding yetSome of those positions are ones almost nobody is selling to yet.
• Interaction screen on the recordEvery active on this label was screened against the interaction record, and the screen is published with it.

The combinations the trials actually measured.

Two pairings in this formula have been studied as combinations in human trials. Each finding below is what a named study measured, cited and dated, never written by the brand.

• Vitamin D3 + Vitamin K2Bone

  In a meta-analysis of eight randomized trials, vitamin K2 taken together with vitamin D raised total bone mineral density and lowered undercarboxylated osteocalcin, a marker of vitamin K status.

  Kuang et al., 2020 (Food & Function)PMID 32219282

  Promising
• Calcium + MagnesiumStrength

  In a 12-month randomised, double-blind trial, 98 adults aged 50 and over drank a litre a day of either a naturally calcium- and magnesium-rich mineral water or a low-mineral water. The mineral-rich group had fewer falls at the 6-month assessment and higher appendicular muscle mass, with the minerals delivered as drinking water rather than a capsule.

  Moretti et al., 2026 (Nutrients)PMID 41683292

  Promising

Findings from trials that studied these actives as a combination. Context for how the actives were tested together, not a statement about any individual and not a claim about this product.

What the trials show about timing.

Time-to-effect windows the engine read from the trial record. Each is a window a named study measured, cited and dated, never written by the brand.

• Vitamin D3about 3 months of daily useBuilds with daily use

  In the trial record, blood vitamin D rises for about 3 months of daily vitamin D3 and then holds at a plateau, near 69 nmol/L at 1,000 IU a day, from a starting level near 41 nmol/L.

  Vieth et al., 2001 (Am J Clin Nutr)PMID 11157326

  Early
• Vitamin K1cleared from plasma within hoursMeasured within a day

  In a stable-isotope study, 10 healthy adults aged 22 to 31 took labelled vitamin K1 for six days and then an intravenous dose to resolve its disposal kinetics. Plasma vitamin K1 cleared with half-times of about 0.22 and 2.66 hours, and absorption of an oral dose was about 13 percent.

  Jones et al., 2008 (European Journal of Clinical Nutrition)PMID 17671443

  Promising
• Vitamin K2about four weeks of daily useBuilds with daily use

  A double-blind randomised dose-finding trial gave 60 postmenopausal women aged 50 to 69 either 0, 50, 100 or 200 micrograms of menaquinone-7 daily for four weeks on a controlled diet. The ratio of carboxylated to undercarboxylated osteocalcin rose dose dependently, with significant differences from the 0 microgram group at 100 and 200 micrograms. A companion 12-week trial in 120 people aged 20 to 69 confirmed the change at 100 micrograms daily. Both studies were run by authors affiliated with the R and D division of J-Oil Mills. An independent 8-week double-blind trial in 55 healthy prepubertal children found the same direction at 45 micrograms daily. What was measured is a blood marker of vitamin K status, not bone density and not a sensation.

  Inaba et al., 2015 (J Nutr Sci Vitaminol (Tokyo))PMID 26875489

  van Summeren et al., 2009 (Br J Nutr)PMID 19450370

  Promising
• Vitamin K2three years of daily use, with measurements at one, two and three yearsBuilds with daily use

  A double-blind randomised trial gave 244 healthy postmenopausal women either placebo or 180 micrograms of menaquinone-7 daily for three years, with bone mineral density measured by DXA at baseline and after each year. Menaquinone-7 decreased the age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck, but not at the total hip. The effect is a slowed decline rather than a gain, and the trial ran three years rather than weeks.

  Knapen et al., 2013 (Osteoporos Int)PMID 23525894

  Promising
• Calciumwithin about one to six hours of a single doseMeasured within a day

  A randomised cross-over trial in ten women of mean age 69 gave a single 500 mg dose of calcium as citrate fasting, citrate with a meal, fortified juice or a dairy product meal, with blood drawn before and at 1, 2, 4 and 6 hours. Serum ionised and total calcium increased significantly from baseline over six hours, with the rise similar after fortified juice, delayed when citrate was taken with a meal and smaller after the dairy meal. A separate double-blind cross-over trial in 25 postmenopausal women measured parathyroid hormone and a bone resorption marker 12 hours after a single calcium dose. Ten participants is a small sample, and what moved was blood chemistry, not a sensation.

  Bristow et al., 2015 (Br J Nutr)PMID 25851635

  Thomas et al., 2008 (Calcif Tissue Int)PMID 18553042

  Promising
• Siliconabout 20 weeks of daily useBuilds with daily use

  In a randomised double blind placebo controlled trial, 50 women with photodamaged facial skin took 10 mg of silicon a day as choline stabilised orthosilicic acid, or placebo, for 20 weeks. Skin roughness rose in the placebo group and fell in the supplemented group, with the change from baseline significantly different between groups for two of the roughness parameters, and self rated brittleness of hair and nails was lower at 20 weeks than at baseline in the supplemented group. Serum silicon was higher in the supplemented group at 20 weeks. The nail and hair readings were visual analogue self ratings, not instrument measurements. The window is recorded for soluble orthosilicic acid, which is the form the trial fed.

  Barel et al., 2005 (Arch Dermatol Res)PMID 16205932

  Early

Windows measured in the cited trials. Context for how the active behaves over time, not a statement about any individual and not a claim about this product.

How each ingredient usually behaves over time.

8 ingredients, from each one's own page.

• Vitamin D3About six to twelve weeks

  25-hydroxyvitamin D climbs over roughly six to twelve weeks of daily dosing before it plateaus. It's a blood level you watch rather than a feeling.

  Its own page, the plain answer on timing ↗

• Vitamin K1Within days

  Clotting factor carboxylation responds within days, and circulating phylloquinone tracks what you ate this week. It reads on a lab measure rather than as a feeling.

  Its own page, the plain answer on timing ↗

• Vitamin K2Days, not hours

  Days for absorption, weeks for the marker. Undercarboxylated osteocalcin falls across roughly four to twelve weeks of daily intake, and that is a status marker rather than an outcome.

  Its own page, the plain answer on timing ↗

• Calcium

  No acute sensation. Parathyroid hormone responds within hours, while bone density shifts over a year or more of steady intake, so this reads on a panel and a scan.

  Its own page, the plain answer on timing ↗

• Magnesium

  A looser stool can turn up the same day at the higher end. Sleep and cramp changes usually settle in across two to four weeks, because it is refilling a body-wide store.

  Its own page, the plain answer on timing ↗

• Strontium

  This works on a months to years timescale. The change is read on a bone density scan rather than noticed, and even then the reading needs correcting first.

  Its own page, the plain answer on timing ↗

How each ingredient usually behaves over time, from its own page on IngredientMD. General timing for the ingredient, not a measurement of this product.

The same ingredient, carried differently.

What each form is, and where it fits in a formula. Measured findings carry the study that reported them.

• Cholecalciferol (vitamin D3)

  The animal-sourced form of vitamin D, made in skin under UVB light and produced commercially from lanolin. Fat-soluble, so it travels with dietary fat and is stored in body fat.

  Fits

  Raising and holding vitamin D status, and the form most supplement trials use.

  Trade-off

  Being fat-soluble it accumulates with sustained high dosing, so intakes are set against the tolerable upper level rather than topped up freely.

  In a 12-week double-blind randomised controlled trial in 108 young women in urban Bangalore, most of whom began vitamin D-deficient, daily vitamin D3 at 400, 600 or 800 IU in a fortified wafer raised serum 25-hydroxyvitamin D, parathyroid hormone fell over time, and effects on bone-turnover markers were modest and not dose specific. The 800 IU dose brought 65 percent of participants to sufficiency.

  Peris et al., 2026 (Nutrients)PMID 42124077

Descriptions of the form itself, read from the cited studies. Not a comparison between products and not a statement about any individual.

Tablet

It is a tablet, so the amount per serving is fixed and it stores well.

Studied alongside this brand's other formulas

Where two of this brand's products carry actives the literature has read together, the pairing and its basis are below. The evidence word is the corpus row's own confidence, never a score.